Your browser doesn't support javascript.
loading
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.
Imai, Masaki; Ito, Mutsumi; Kiso, Maki; Yamayoshi, Seiya; Uraki, Ryuta; Fukushi, Shuetsu; Watanabe, Shinji; Suzuki, Tadaki; Maeda, Ken; Sakai-Tagawa, Yuko; Iwatsuki-Horimoto, Kiyoko; Halfmann, Peter J; Kawaoka, Yoshihiro.
Afiliação
  • Imai M; University of Tokyo, Tokyo, Japan.
  • Ito M; University of Tokyo, Tokyo, Japan.
  • Kiso M; University of Tokyo, Tokyo, Japan.
  • Yamayoshi S; University of Tokyo, Tokyo, Japan.
  • Uraki R; University of Tokyo, Tokyo, Japan.
  • Fukushi S; National Institute of Infectious Diseases, Tokyo, Japan.
  • Watanabe S; National Institute of Infectious Diseases, Tokyo, Japan.
  • Suzuki T; National Institute of Infectious Diseases, Tokyo, Japan.
  • Maeda K; National Institute of Infectious Diseases, Tokyo, Japan.
  • Sakai-Tagawa Y; University of Tokyo, Tokyo, Japan.
  • Iwatsuki-Horimoto K; University of Tokyo, Tokyo, Japan.
  • Halfmann PJ; University of Wisconsin-Madison, Madison, WI.
  • Kawaoka Y; University of Tokyo, Tokyo, Japan yoshihiro.kawaoka@wisc.edu.
N Engl J Med ; 388(1): 89-91, 2023 01 05.
Article em En | MEDLINE | ID: mdl-36476720
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / SARS-CoV-2 / COVID-19 / Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / SARS-CoV-2 / COVID-19 / Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article